Clinical trial NCT02127892: SCID Bu/Flu/ATG Study With T Cell Depletion
Official title: Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Severe Combined Immunodeficiency
Keywords: Severe Combined Immune Deficiency
SCID
HLA-matched unrelated donor
unrelated
MUD
bone marrow
cord blood
haplo-identical
peripheral blood
CD34+ selection
T cell depletion
HSCT
BMT
CliniMACS
Lead sponsor: Children's Hospital Los Angeles
Sponsor class: OTHER
First posted: 2014-05-01
Enrollment: 9
Sex: ALL
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with a diagnosis of Severe Combined Immune Deficiency (SCID) who do not have an HLA-matched sibling donor. The stem cells will be derived from a 1) matched unrelated donor (MUD), 2) unrelated cord blood donor, or 3) a haplo-identical (parental) donor (in descending order of preference).Patients will receive a novel conditioning regimen with Busulfan, Fludarabine and Anti-thymocyte globulin (ATG) followed by an unrelated donor hematopoietic stem cell transplant (HSCT) with T-cell depletion using the CliniMACS device.

Detailed description: The study is being conducted to assess the following:

* overall survival
* event-free survival (events are defined as: death,non-engraftment/2nd transplant, immune reconstitution failure)
* acute toxicity of the conditioning regimen
* engraftment frequency immune reconstitution frequency and tempo acute and chronic graft-versus-host disease (GVHD), frequency and severity.

The outcome from this protocol will be compared to the retrospective cohort consisting of all patients who have undergone haplo-identical HSCT for SCID at CHLA from 1984-2006 based on the assessment of the above-listed endpoints.

The CliniMACS device will be used for CD34+ selection in place of the Isolex 300i. The CliniMACS CD34 Reagent System is an investigational medical device that has not yet been approved by the FDA. This device is used in vitro to select and enrich specific cell populations. When using the CliniMACS CD34 Reagent, the system selects CD34+ cells from heterogenous hematological cell populations for transplantation in cases where this is clinically indicated.

Eligibility criteria: Inclusion Criteria:

* All patients with SCID who lack a histocompatible sibling or HLA-matched related donor will be considered as candidates for this study protocol.
* Eligible patients must have adequate physical function to tolerate the chemotherapy conditioning regimen and the HSCT, as measure by:

  1. Renal: creatinine clearance or GFR ≥50 ml/min/1.73m2, and not requiring dialysis
  2. Pulmonary: Because patients with SCID frequently present with infectious pneumonia causing ventilatory failure, patients will be considered for enrollment in the study even if respiratory failure requiring mechanical ventilatory support is present. In patients recently diagnosed with pneumonia, efforts to stabilize the respiratory status will be made prior to enrollment in the study.
  3. Infectious disease status. The presence of infection per se will not be a reason for exclusion from the study. Patients with SCID are frequently infected with both routine pathogens as well as opportunistic infections. Antibiotic, antifungal and antiviral prophylaxis and therapy will be instituted as clinically indicated. Despite the use of antimicrobial therapy, the ability to control infections will not be achieved unless HSCT is performed. Therefore, subjects may be enrolled in the study, even though infection is present, because control of infection may depend on engraftment of a donor immune system.
  4. Patients will be 0-21 years of age.

Exclusion Criteria:

* Patient with histocompatible sibling or other related donor
* End-organ failure that precludes the ability to tolerate the transplant procedure, including conditioning.
* Renal failure requiring dialysis
* Congenital heart disease resulting in congestive heart failure
* Severe CNS disease, e.g., coma or intractable seizures
* Ventilatory failure due to non-infectious etiology
* Major congenital anomalies that adversely affect survival, eg CNS malformations
* Metabolic diseases that would affect transplant survival, eg urea cycle disorders
* HIV infection

Since the only chance of survival for patients with SCID is successful transplantation, all patients with SCID will be considered to be potential subjects for the study, regardless of end-organ dysfunction.

Primary outcomes:
measure: Number of Participants With Engraftment
timeFrame: 100 day
Secondary outcomes:
measure: Number of Participants With Donor-derived CD3+ T Lymphocytes >/= 100/mm3
timeFrame: 1 year
Other outcomes:
measure: Number of Participants With Veno-occlusive Disease (VOD) - Moderate and Severe
timeFrame: 100 days
measure: Number of Participants With Graft Versus Host Disease (GVHD) - Grade III or IV
timeFrame: 1 year
measure: Overall Survival
timeFrame: 1 year
Locations:
city: Los Angeles
country: United States
facility: Children's Hospital Los Angeles
state: California
Study officials:
affiliation: Children's Hospital Los Angeles, University of Southern California
name: Neena Kapoor, M.D.
role: PRINCIPAL_INVESTIGATOR
References: